TABLE A4

Summary of the Incidence of Nonneoplastic Lesions in *Ad Libitum*-Fed Male Mice in the 2-Year Gavage Study of Chloral Hydrate^a

	Vehicle Control	25 mg/kg	50 mg/kg	100 mg/kg
Disposition Summary				
Animals initially in study 15-Month interim evaluation	60 12	60 12	60 12	60 12
Early deaths Moribund Natural deaths	6	4 7	2 10	1 3
Survivors Terminal sacrifice	42	37	36	44
Animals examined microscopically	60	60	60	60
15-Month Interim Evaluation				
Alimentary System				
Liver	(12)	(12)	(12)	(12)
Fatty change, focal, peripheral	2 (17%)	7 (58%)		
Fatty change, peripheral	2 (25%)		7 (58%)	7 (58%)
Granuloma, multiple Vacuolization cytoplasmic, centrilobular	3 (25%) 9 (75%)	5 (42%)	6 (50%)	4 (33%)
2-Year Study				
Alimentary System				
Esophagus	(47)	(11)	(11)	(48)
Autolysis	4 (9%)		1 (9%)	1 (20/)
Polyarteritis Gallbladder	(43)	(10)	(10)	1 (2%) (44)
Autolysis	2 (5%)	4 (40%)	6 (60%)	1 (2%)
Crystals, epithelium	1 (2%)	1 (10/0)	0 (00/0)	1 (270)
Cyst			1 (10%)	
Fibrosis				2 (5%)
Inflammation, chronic, serosa				1 (2%)
Intestine large, cecum	(41)	(5)	(4)	(46)
Autolysis Hyperplasia, lymphoid				1 (2%) 1 (2%)
Polyarteritis				1 (2%) 1 (2%)
Intestine large, colon	(41)	(5)	(4)	(46)
Autolysis				1 (2%)
Polyarteritis				1 (2%)
Intestine large, rectum	(41)	(5)	(4)	(43)
Granuloma	1 (2%)			1 (20/)
Polyarteritis Intestine small, duodenum	(41)	(7)	(4)	1 (2%) (46)
Autolysis	(+1)	1 (14%)	(ד)	1 (2%)
Intestine small, ileum	(42)	(5)	(5)	(46)
Autolysis				1 (2%)
Intestine small, jejunum	(42)	(5)	(4)	(46)
Autolysis				1 (2%)

^a Number of animals examined microscopically at the site and the number of animals with lesion

	Vehicle	Control	25 1	mg/kg	50 r	ng/kg	100	mg/kg
2-Year Study (continued)								
Alimentary System (continued)								
Liver	(48)		(48)		(47)		(48)	
Autolysis	· · ·	(6%)		(4%)	(47)			(2%)
Basophilic focus		(6%)		(6%)	1	(2%)		(2%) (10%)
Clear cell focus		(2%)		(0%)		(6%)		(4%)
Clear cell focus, multiple		· /	1	(2%)		· · ·		
ý 1	1	(2%)		2	(4%)		(2%)	
Congestion			1	(20/)		(2%)	1	(20/)
Eosinophilic focus				(2%)	1	(2%)	1	(2%)
Fatty change, focal			1	(2%)	1	(20())		
Fibrosis, focal	1	(20())				(2%)		
Granuloma, multiple	1	(2%)		(20)	1	(2%)		
Hyperplasia, bile duct				(2%)				(
Infarct	-		2	(4%)				(4%)
Infiltration cellular, lymphocytic	2	(4%)		(20)	1	(2%)	2	(4%)
Mixed cell focus			1	(2%)				
Necrosis, focal, hepatocyte					1	(2%)		
Necrosis, hepatocyte		(2%)	1	(2%)				
Necrosis, multifocal, hepatocyte	1	(2%)						
Regeneration, focal				(2%)				
Vacuolization cytoplasmic, centrilobular		(4%)		(2%)		(4%)		(8%)
Pancreas	(46)		(10)		(9)		(48)	
Atrophy, acinar cell			1	(11%)				
Autolysis	4	(9%)			2	(22%)	1	(2%)
Cyst, duct				(10%)				
Fibrosis			1	(10%)				
Polyarteritis							1	(2%)
Salivary glands	(48)		(10)		(10)		(48)	
Autolysis	5	(10%)						
Degeneration	1	(2%)						
Infiltration cellular, lymphocytic	9	(19%)	2	(20%)			10	(21%)
Stomach, forestomach	(43)		(10)		(10)		(46)	
Autolysis	1	(2%)			1	(10%)		
Hyperkeratosis, focal	1	(2%)						
Hyperplasia, squamous	1	(2%)						
Stomach, glandular	(43)		(10)		(10)		(46)	
Autolysis	2	(5%)	4	(40%)	5	(50%)		
Inflammation, acute, submucosa	1	(2%)						
Inflammation, chronic, focal							1	(2%)
Polyarteritis							1	(2%)
Tongue	(47)		(10)		(11)		(47)	. ,
Autolysis		(9%)	(-)			(9%)		
Polyarteritis						- *	1	(2%)
Cardiovascular System								
Blood vessel	(48)		(11)		(11)		(48)	
Autolysis, aorta	3	(6%)						

TABLE A4

	Vehicle Control	25 mg/kg	50 mg/kg	100 mg/kg		
2-Year Study (continued) Cardiovascular System (continued) Heart Autolysis Cardiomyopathy Congestion Hemorrhage, myocardium Polyarteritis	(48) 3 (6%) 1 (2%)	(11) 1 (9%)	(11) 1 (9%) 1 (9%)	(48) 1 (2%) 1 (2%)		
Endocrine System Adrenal gland, cortex Autolysis Cyst, unilateral Cytologic alterations Cytoplasmic alteration Degeneration, focal, unilateral Hyperplasia, spindle cell Hypertrophy Adrenal gland, medulla Autolysis Hyperplasia Parathyroid gland Autolysis Cyst Pituitary gland Autolysis Cyst Hyperplasia, focal, pars distalis Thyroid gland Autolysis Cyst Hyperplasia, focal, pars distalis	(45) 4 (9%) 1 (2%) 1 (2%) 4 (9%) 6 (13%) 24 (53%) 2 (4%) (45) 3 (7%) (47) 4 (9%) 1 (2%) (42) 3 (7%) 2 (5%) 1 (2%) (47) 4 (9%) 5 (11%)	$(11) \\ 2 (18\%) \\ 2 (18\%) \\ 7 (64\%) \\ (11) \\ (6) \\ (10) \\ 2 (20\%) \\ (11) \\ 1 (9\%) $	 (10) 2 (20%) 1 (10%) 3 (30%) (10) 1 (10%) (6) 1 (17%) (9) 1 (11%) (10) 3 (30%) 	(46) 1 (2%) 1 (2%) 5 (11%) 1 (2%) 4 (9%) 27 (59%) (45) 1 (2%) 1 (2%) (42) (46) 1 (2%) 1 (2%) (48) 3 (6%) 1 (2%) (2%) (48) 3 (6%) 1 (2%) (2%) (46) 1 (2%) (2%) (48) 3 (6%) 1 (2%) (42) (48) (2%) (48) (2%) (48) (48) (48) (2%) (48) (48) (48) (2%) (48)		
General Body System None						
Genital System Coagulating gland Autolysis Distended Inflammation, chronic active Epididymis Autolysis Granuloma sperm Granuloma, unilateral Infiltration cellular, lymphocytic Inflammation, chronic active Inflammation, chronic Polyarteritis	(46) 3 (7%) (46) 3 (7%) 1 (2%) 1 (2%)	(10) 1 (10%) (10) 1 (10%)	(10) 2 (20%) 1 (10%) 1 (10%) (11) 2 (18%) 1 (9%)	(48) 1 (2%) (48) 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%)		

TABLE A4

	Vehicle	e Control	25 1	mg/kg	50 r	ng/kg	100	mg/kg
2-Year Study (continued)								
Genital System (continued)								
Penis						(1)		
Concretion						(1)	1	(100%)
Inflammation, acute								(100%)
Preputial gland	(46)		(10)	(11)		(48)		()
Abscess			· · ·	(10%)		(- /		
Atrophy	15	(33%)		(40%)	6 (55%)	21	(44%)	
Autolysis		(7%)				(9%)		
Cyst		(2%)			1	(9%)	3	(6%)
Dilatation		(2%)				. ,	1	(2%)
Ectasia, duct			2	(20%)	5	(45%)		(4%)
Inflammation, acute, unilateral				· · ·				(2%)
Inflammation, chronic, unilateral	1	(2%)						. ,
Inflammation		(2%)						
Prostate	(46)		(10)		(11)		(48)	
Atrophy	2	(4%)	. ,				3	(6%)
Autolysis	3	(7%)			3	(27%)		
Congestion		· /			1	(9%)		
Ectasia, focal					1	(9%)		
Inflammation, acute							1	(2%)
Inflammation, focal							1	(2%)
Polyarteritis							1	(2%)
Seminal vesicle	(46)		(11)		(14)		(48)	
Atrophy	1	(2%)					2	(4%)
Autolysis	3	(7%)	1	(9%)	2	(14%)	1	(2%)
Depletion					1	(7%)		
Dilatation	1	(2%)					1	(2%)
Distended			1	(9%)	3	(21%)		
Inflammation, chronic active					1	(7%)		
Inflammation, chronic							1	(2%)
Polyarteritis, unilateral							1	(2%)
Testes	(45)		(11)		(10)		(48)	
Atrophy, unilateral	1	(2%)						
Autolysis	3	(7%)	1	(9%)	3	(30%)	1	(2%)
Degeneration, bilateral	1	(2%)						
Hyperplasia, unilateral, interstitial cell							1	(2%)
Hematopoietic System								
Bone marrow	(47)		(10)		(10)		(48)	
Autolysis	· · ·	(6%)	(10)		(10)		(40)	
Hyperplasia		(0%)	2	(20%)	2	(20%)	4	(8%)
Lymph node	(48)	(270)	(15)	(20/0)	(17)	· /	(48)	. ,
Granuloma, inguinal	· · ·	(2%)	(13)		(17)		(40)	
Lymph node, mandibular	(48)	(270)	(10)		(9)		(45)	
Autolysis	· · ·	(8%)	(10)		()		(43)	
Hyperplasia	4	(070)					1	(2%)
Inflammation, chronic			1	(10%)			1	(270)
			1	(10/0)				

TABLE A4

	Vehicle Control	25 mg/kg	50 mg/kg	100 mg/kg	
2-Year Study (continued) Hematopoietic System (continued)					
Lymph node, mesenteric Angiectasis, focal	(47)	(13)	(16) 1 (6%)	(48)	
Autolysis Congestion	5 (11%)		1 (6%)	1 (2%)	
Degeneration Granuloma	4 (9%)	4 (31%)	5 (31%) 1 (6%)	5 (10%)	
Hematopoietic cell proliferation	1 (2%)			1 (20())	
Hemorrhage Hyperplasia Polyarteritis, artery	1 (2%) 1 (2%)		1 (6%)	1 (2%) 4 (8%) 1 (2%)	
Spleen	(47)	(16)	(17)	(48)	
Angiectasis, focal Apoptosis, lymphocyte		1 (6%)	1 (6%)	2 (10/)	
Atrophy, lymphocyte Autolysis Congestion	4 (9%)	3 (19%) 1 (6%)	1 (6%) 2 (12%)	2 (4%)	
Hematopoietic cell proliferation	2 (4%)	7 (44%)	2 (12%)	7 (15%)	
Hyperplasia, lymphoid Thymus	3 (6%) (29)	(6)	3 (18%) (4)	1 (2%) (35)	
Autolysis Ectopic parathyroid gland	3 (10%)	1 (17%)		1 (3%)	
Integumentary System Mammary gland Autolysis Skin Autolysis Granuloma	(5) 2 (40%) (48) 4 (8%) 1 (2%)	(10)	(2) (10) 1 (10%)	(48)	
Musculoskeletal System					
Bone, femur	(46)	(11)	(12)	(48)	
Autolysis Bone, sternum	3 (7%) (47)	(11)	(12)	(48)	
Autolysis	3 (6%)				
Fibrous osteodystrophy Polyarteritis	4 (9%)			2 (4%) 1 (2%)	
Skeletal muscle Autolysis	(47) 4 (9%)	(10)	(11) 1 (9%)	(48)	
Infiltration cellular, lymphocytic Mineralization, focal	1 (2%)			1 (2%)	
Polyarteritis	1 (278)			2 (4%)	
Nervous System	(17)				
Brain, cerebellum Autolysis	(47) 4 (9%)	(10) 1 (10%)	(9)	(48) 1 (2%)	
Brain, cerebrum	(47)	(10)	(9)	(48)	
Autolysis Hydrocephalus	4 (9%)	1 (10%)		1 (2%) 1 (2%)	
Mineralization, thalamus	25 (53%)	2 (20%)	1 (11%)	14(29%)	

TABLE A4

	Vehicle Control	25 mg/kg	50 mg/kg	100 mg/kg
2-Year Study (continued) Nervous System (continued) Peripheral nerve Autolysis Degeneration Demyelination Infiltration cellular, lymphocytic Spinal cord	(47) 4 (9%) 2 (4%) 1 (2%) 1 (2%) (47)	(10)	(11) 1 (9%) (9)	(48) 1 (2%) (48)
Autolysis	4 (9%)	1 (10%)		1 (2%)
Respiratory System Larynx Autolysis Polyarteritis Lung Atelectasis Autolysis Congestion Dilatation, bronchiole, glands Hemorrhage, focal, alveolus Hyperplasia, alveolar epithelium Infiltration cellular, lymphocytic Inflammation, chronic active Polyarteritis Nose Autolysis Trachea Autolysis Dilatation, glands	$(46) 4 (9%) (48) 3 (6%) 1 (2%) 4 (8%) (47) 4 (9%) (47) 4 (9%) 1 (2%) }$	 (11) (20) 1 (5%) 1 (5%) (11) (10) 	 (11) (9%) (16) (6%) (6%) (6%) (12) (8%) (11) (9%) 	 (47) 1 (2%) (48) 1 (2%) 2 (4%) 2 (4%) 1 (2%) (48) (48)
Special Senses System Eye Autolysis Cataract, lens Polyarteritis Harderian gland Atrophy, focal, unilateral Autolysis Hyperplasia, diffuse, unilateral Hyperplasia, focal, bilateral Hyperplasia, focal, unilateral Hyperplasia, notal Hyperplasia, napillary, unilateral Infiltration cellular, lymphocytic Lacrimal gland Atrophy, focal Autolysis Cytoplasmic alteration	$(46) \\ 3 (7\%) \\ (47) \\ 1 (2\%) \\ 4 (9\%) \\ 1 (2\%) \\ 1 (2\%) \\ 5 (11\%) \\ (47) \\ 1 (2\%) \\ 5 (11\%) \\ (1\%$	(11) 1 (9%) (16) ¹ (6%) (10)	$\binom{(11)}{2}$ (18%) (12) 1 (8%) $\binom{2}{(10)}$ (17%)	 (48) 1 (2%) (47) 1 (2%) 1 (2%) 1 (2%) 1 (2%) (46) 1 (2%)
Infiltration cellular, lymphocytic Zymbal's gland Autolysis	(45) 2 (4%)	(9)	(7)	(48)

TABLE A4

	Vehicle Control		25 mg/k	g 50 i	50 mg/kg		100 mg/kg	
2-Year Study (continued)								
Urinary System								
Kidney	(46)		(10)	(10))	(48)		
Accumulation hyaline droplet, renal tubule			2 (20%))				
Angiectasis						1	(2%)	
Autolysis	5	(11%)	1 (10%	o) 4	(40%)	1	(2%)	
Congestion				1	(10%)			
Cyst, renal tubule	5	(11%)					(6%)	
Degeneration, renal tubule	5	(11%)				3	(6%)	
Glomerulosclerosis	2	(4%)	4 (40%) 1	(10%)	10	(21%)	
Hydronephrosis					2 (20%)			
Infarct, unilateral	2	(4%)	1 (10%)		1	(2%)	
Infiltration cellular, lymphocytic				1 (10%)	3	(6%)		
Inflammation, chronic	1	(2%)						
Mineralization, renal tubule	4	(9%)	1 (10%)			(6%)	
Nephropathy	6	(13%)		1	(10%)	3	(6%)	
Regeneration, renal tubule	11	(24%)				7	(15%)	
Vacuolization cytoplasmic, bilateral,								
renal tubule	1	(2%)						
Urinary bladder	(46)		(10)	(11))	(48)		
Autolysis	3	(7%)		3	(9%)			
Infiltration cellular, lymphocytic	4	(9%)						
Inflammation, acute						1	(2%)	